AI Insight
This phase 3 trial in China compared izalontamab brengitecan (iza-bren), a bispecific antibody-drug conjugate, to platinum-based chemotherapy in patients with EGFR-mutated advanced non-squamous non-small-cell lung cancer who had disease progression after third-generation EGFR tyrosine kinase inhibitors. Iza-bren significantly extended progression-free survival compared to chemotherapy, though it was associated with higher rates of severe treatment-related adverse events (grade 3 or worse). This represents the first phase 3 evidence supporting the efficacy of a bispecific antibody-drug conjugate in this clinical setting.
Why it matters
Patients with EGFR-mutated lung cancer who progress after third-generation EGFR inhibitors have limited treatment options. This study establishes iza-bren as a potential new therapeutic alternative for this population, offering improved disease control despite increased toxicity risks.
Understand the Science
In participants with EGFR-mutated advanced non-squamous NSCLC after progression on third-generation EGFR TKIs, iza-bren significantly prolonged progression-free survival, although treatment-related adverse events of grade 3 or worse were more frequent than with chemotherapy. To our knowledge, these findings provide the first phase 3 evidence for a bispecific antibody–drug conjugate and support iza-bren as a potential treatment option in this population.